Pancreatic Cancer News and Research

RSS

Pancreatic cancer is the fourth leading cause of all cancer deaths in the United States and the third leading cause of cancer deaths in individuals ages 40 to 60. Approximately 37,000 Americans are diagnosed with pancreatic cancer each year, and, each year, approximately the same number die from it. Often, pancreatic cancer is found too late for surgical intervention, and chemotherapy and radiation treatments have little effect.

Discovery of key molecule that controls the growth, spread and survival of pancreatic cancer cells

Pancreatic cancer kills 30,000 Americans every year. Not only is there no cure, but there are no effective treatments. That may change if a new finding by Mayo Clinic researchers continues to show promise.

15 Mar 2005

Thalidomide - new treatment for cancer

Thalidomide, famous in the 60's because of limb deformities in babies born to women who had taken it for morning sickness, was withdrawn in 1961. Now doctors say it could be used as a treatment for cancer.

8 Mar 2005

Thalidomide may have a new lease of life as a cancer treatment

The drug thalidomide may have a new lease of life as a cancer treatment. A small study published in Gut suggests that it slows down the weight loss and wasting associated with advanced disease in patients with pancreatic cancer.

7 Mar 2005

Targeting the Hedgehog pathway could be used in the treatment of neurodegenerative diseases

Aberrant activation of the Hedgehog (Hh) pathway has been associated with numerous malignancies including basal cell carcinoma, medulloblastoma, and pancreatic cancer. Several reports also suggest that positive regulators of the Hh pathway could be used in the treatment of neurodegenerative diseases.

27 Feb 2005

Avastin available across Europe within the next few weeks

Roche has announced that the European Commission has approved Avastin (bevacizumab, rhuMAb-VEGF), the new innovative anti-angiogenesis drug, for the treatment of patients with previously untreated metastatic colorectal cancer.

16 Jan 2005

Evaluation of BAY 43-9006 (Sorafenib) for pancreatic cancer

Oncologists from USC/Norris Comprehensive Cancer Center are running tests on a new pancreatic cancer drug that targets the cancer from two directions.

13 Jan 2005

Elevated glucose levels and diabetes associated with a greater risk for cancer

New research involving more than one million people indicates that having high fasting serum glucose levels and diabetes are risk factors for several major cancers, according to a study in the January 12 issue of JAMA.

12 Jan 2005

Elevated blood sugar levels and diabetes are risk factors for developing several types of cancer and mortality

The researchers followed over 1.2 million Koreans for 10 years, tracking new cancer cases and deaths from cancer. Study participants with diabetes, as well as those without diabetes and higher fasting blood sugar levels, were more likely to develop cancer or to die from cancer.

11 Jan 2005

Potential new therapies for cancer and bleeding disorders

Lexicon Genetics announced today that it has advanced two of its drug discovery programs into preclinical development in preparation for investigational new drug (IND) applications.

10 Jan 2005

Using precise, radioactively labeled genetic probes, researchers study cancer gene activity from outside the body

Using precise, radioactively labeled genetic probes, researchers at Jefferson Medical College have seen cancer gene activity from outside the body in laboratory mice. The probes, which work by attaching to genetic codes copied from an active cancer gene, may someday aid physicians and scientists in cancer detection and in determining the appropriate treatment for a cancer.

13 Dec 2004

Study clarifies BRCA1 and BRCA2 links with other cancers

The largest population study ever done into the risk of cancer in families that fulfil the criteria for BRCA1 and BRCA2 mutation testing has confirmed that breast and ovarian cancers are the major concerns for geneticists and doctors counselling families.

14 Nov 2004

Tobacco may trigger pancreatic cancer

A new study finds tobacco may act as an environmental trigger for patients with an inherited genetic predisposition to pancreatic cancer.

8 Nov 2004

New molecular tool to pinpoint DNA mutations among thousands of cells

Scientists have designed a new molecular tool, dubbed "LigAmp," to pinpoint DNA mutations among thousands of cells, the equivalent of searching for a single typo in an entire library of books.

28 Oct 2004

New medication to prevent colon cancer

A Stony Brook University researcher is testing a new form of aspirin--one that is much more potent than its commercially available counterpart, but with almost none of the side effects--to determine whether it can be used to prevent colon cancer in patients who are prone to the disease.

21 Oct 2004

People with diabetes mellitus have three to four times the risk of developing liver cancer

People with diabetes mellitus have three to four times the risk of developing liver cancer, and more than twice the risk of developing pancreatic cancer than non-diabetic individuals, according to research presented at the Third Annual Frontiers in Cancer Prevention Research Meeting in Seattle.

18 Oct 2004

Aspirin might well be considered the top utility player in the medicine cabinet

This cheap over-the-counter drug can be used not only for fever, pain and arthritis, but to prevent heart attack, stroke or angina. It also may reduce the risk of colorectal cancer. Yet aspirin also has side effects worth considering, and its very accessibility may hamper its use.

8 Oct 2004

Tarceva plus Gemcitabine improves survival compared to Gemcitabine alone

OSI Pharmaceuticals, Inc., Genentech, Inc., and Roche announced today that results from a randomized Phase III clinical study of the investigational drug Tarceva (erlotinib HCl), in combination with gemcitabine chemotherapy met its primary endpoint of improving survival.

20 Sep 2004

Bladder-sparing treatment shows promise against cancer

For patients with invasive bladder cancer, treatment has typically meant an operation to remove the bladder and nearby organs. This requires up to a week in the hospital and leaves patients with a reconstructed bladder or urostomy bag.

21 Jul 2004

Benefits of current therapeutic options for pancreatic cancer are eclipsed by their toxicity and inconvenience

Decision Resources, Inc., one of the world's leading research and advisory firms focusing on pharmaceutical and health care issues, finds that the benefits of current therapeutic options for pancreatic cancer are eclipsed by their toxicity and inconvenience, especially in advanced stages of the disease.

15 Jun 2004

Drug Tarceva improves survival chance for patients with advanced lung cancer

Roche OSI Pharmaceuticals and Genentech today announced that their investigational drug Tarceva(TM) (erlotinib) achieved a significant 42.5% improvement in median survival compared to placebo in patients with advanced non-small cell lung cancer (NSCLC).

5 Jun 2004